Last 7 days
4.2%
Last 30 days
-15.3%
Last 90 days
-14.0%
Trailing 12 Months
-74.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 125.3B | 26.3B | -2.75% | 3.76% | 19.12 | 4.76 | 1.32% | 11.18% |
GILD | 99.6B | 27.3B | -8.96% | 41.01% | 21.68 | 3.65 | -0.09% | -26.23% |
MRNA | 58.4B | 19.3B | -12.76% | 1.00% | 6.99 | 3.03 | 4.29% | -31.47% |
BIIB | 38.3B | 10.2B | -9.67% | 32.94% | 12.57 | 3.76 | -7.36% | 95.80% |
MID-CAP | ||||||||
NBIX | 9.1B | 1.5B | -9.09% | 3.35% | 58.87 | 6.11 | 31.34% | 72.43% |
DNLI | 3.2B | 108.5M | -21.10% | -19.55% | -9.78 | 29.38 | 122.90% | -12.19% |
BEAM | 2.5B | 60.9M | -18.47% | -36.46% | -8.76 | 41.55 | 17.51% | 22.00% |
BBIO | 2.1B | 107.9M | 22.95% | 67.45% | -4.29 | 19.27 | 54.84% | 17.36% |
SMALL-CAP | ||||||||
RCUS | 1.2B | 112.0M | -14.86% | -46.41% | -4.63 | 11.04 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -22.18% | 24.65% | -7.11 | 158.97 | 131.81% | -45.39% |
FATE | 541.9M | 96.3M | -12.99% | -82.24% | -1.92 | 5.63 | 72.44% | -32.79% |
NVAX | 513.7M | 2.0B | -39.67% | -92.01% | -0.78 | 0.26 | 72.89% | 62.27% |
SGMO | 355.3M | 111.3M | -30.55% | -58.78% | -1.85 | 3.19 | 0.54% | -7.86% |
VXRT | 101.4M | 159.0K | -16.47% | -82.96% | -0.97 | 637.62 | -86.46% | -64.56% |
IBIO | 25.1M | - | 94.03% | -77.12% | -0.31 | 3.21 | 0.51% | -185.61% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -0.5% | 30,000,000 | 30,155,000 | 20,999,000 | 11,843,000 | 2,687,000 |
Operating Expenses | -2.5% | 91,869,000 | 94,213,000 | 91,199,000 | 85,678,000 | 78,700,000 |
S&GA Expenses | -5.0% | 24,866,000 | 26,175,000 | 26,018,000 | 26,026,000 | 25,128,000 |
R&D Expenses | -1.5% | 67,003,000 | 68,038,000 | 65,181,000 | 59,652,000 | 53,572,000 |
EBITDA | 0.4% | -74,506,000 | -74,773,000 | - | - | - |
EBITDA Margin | 0.4% | -27.73 | -27.83 | - | - | - |
EBT Margin | 0% | -29.21 | -29.21 | - | - | - |
Interest Expenses | 7.4% | 3,146,000 | 2,929,000 | 2,521,000 | 2,204,000 | 2,546,000 |
Net Income | 4.1% | -63,586,000 | -66,304,000 | -62,957,000 | -56,725,000 | -78,485,000 |
Net Income Margin | 3.6% | -2.12 | -2.20 | -23.43 | - | - |
Free Cahsflow | -11.4% | -60,049,000 | -53,928,000 | -50,352,000 | -67,102,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -12.0% | 160 | 182 | 194 | 218 | 191 |
Current Assets | -14.0% | 129 | 150 | 162 | 184 | 157 |
Cash Equivalents | -21.8% | 51.00 | 65.00 | 75.00 | 66.00 | 56.00 |
Net PPE | -1.2% | 5.00 | 5.00 | 5.00 | 5.00 | 6.00 |
Liabilities | -3.3% | 67.00 | 69.00 | 68.00 | 71.00 | 72.00 |
Current Liabilities | -9.6% | 16.00 | 18.00 | 20.00 | 20.00 | 20.00 |
Shareholder's Equity | -17.2% | 93.00 | 113 | 126 | 147 | 119 |
Retained Earnings | -11.7% | -204 | -183 | -159 | -134 | -140 |
Additional Paid-In Capital | 0.5% | 299 | 297 | 287 | 282 | 260 |
Accumulated Depreciation | - | 8.00 | - | - | - | - |
Shares Outstanding | 0.1% | 61.00 | 61.00 | 55.00 | 54.00 | 47.00 |
Cashflow (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -11.0% | -59,552 | -53,655 | -50,086 | -66,947 | -62,344 |
Share Based Compensation | -4.3% | 7,223 | 7,547 | 7,825 | 8,031 | 8,546 |
Cashflow From Investing | 316.0% | 22,757 | 5,471 | -3,032 | -16,153 | -99,252 |
Cashflow From Financing | -39.6% | 31,660 | 52,432 | 44,607 | 48,231 | 42,500 |
95.0%
94.6%
93.4%
Y-axis is the maximum loss one would have experienced if Surface Oncology was unfortunately bought at previous high price.
-32.9%
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-02-21 | MACQUARIE GROUP LTD | unchanged | - | -77,000 | 287,000 | -% |
2023-02-15 | JANE STREET GROUP, LLC | new | - | 107,887 | 107,887 | -% |
2023-02-15 | Belvedere Trading LLC | new | - | 2,338 | 2,338 | -% |
2023-02-14 | TWO SIGMA ADVISERS, LP | reduced | -21.8 | -17,464 | 28,536 | -% |
2023-02-14 | TWO SIGMA SECURITIES, LLC | new | - | 12,701 | 12,701 | -% |
2023-02-14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | added | 108 | 15,848 | 40,848 | -% |
2023-02-14 | Bank of New York Mellon Corp | reduced | -26.75 | -78,438 | 108,562 | -% |
2023-02-14 | Laurion Capital Management LP | unchanged | - | -146,372 | 545,628 | -% |
2023-02-14 | DAFNA Capital Management LLC | reduced | -28.82 | -501,940 | 642,060 | 0.18% |
2023-02-14 | MARSHALL WACE, LLP | reduced | -46.4 | -125,039 | 90,961 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | ecor1 capital, llc | 6.5% | 3,924,713 | SC 13G/A | |
Jan 31, 2023 | atlas venture fund ix, l.p. | 4.87% | 2,945,453 | SC 13G/A | |
May 09, 2022 | blackrock inc. | 4.6% | 2,502,271 | SC 13G | |
Mar 14, 2022 | ecor1 capital, llc | 9.9% | 4,653,000 | SC 13G | |
Feb 10, 2022 | eli lilly & co | 3.5% | 1,593,997 | SC 13G/A | |
Feb 09, 2022 | ark investment management llc | 11.54% | 5,326,127 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
Feb 04, 2022 | blackrock inc. | 5.6% | 2,562,685 | SC 13G | |
Jan 25, 2022 | atlas venture fund ix, l.p. | 6.38% | 2,945,453 | SC 13G/A | |
Jul 09, 2021 | ark investment management llc | 10.31% | 4,476,420 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 09, 2023 | 10-K | Annual Report | |
Mar 09, 2023 | 8-K | Current Report | |
Mar 09, 2023 | S-8 | Employee Benefits Plan | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Feb 13, 2023 | SC 13G/A | Major Ownership Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2022-08-03 | FEES JESSICA | sold | -10,285 | 1.72 | -5,980 | chief financial officer |
2022-08-03 | ROSS ROBERT W. | sold | -18,221 | 1.72 | -10,594 | chief executive officer |
2022-08-03 | RATH HENRY C. | sold | -9,762 | 1.72 | -5,676 | chief business officer |
2022-08-03 | Palombella Vito J. | sold | -7,676 | 1.72 | -4,463 | chief scientific officer |
2022-08-03 | ONEILL ALISON | sold | -7,676 | 1.72 | -4,463 | chief medical officer |
2022-03-01 | FEES JESSICA | acquired | - | - | 38,000 | chief financial officer |
2022-03-01 | ONEILL ALISON | acquired | - | - | 38,000 | chief medical officer |
2022-03-01 | ROSS ROBERT W. | acquired | - | - | 56,000 | chief executive officer |
2022-03-01 | RATH HENRY C. | acquired | - | - | 38,000 | chief business officer |
2022-03-01 | Palombella Vito J. | acquired | - | - | 38,000 | chief scientific officer |
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Statement of Comprehensive Income [Abstract] | |||
Collaboration revenue - related party | $ 0 | $ 0 | $ 38,592 |
License-related revenue | 30,000 | 2,687 | 87,570 |
Total revenue | 30,000 | 2,687 | 126,162 |
Operating expenses: | |||
Research and development | 67,003 | 53,572 | 41,018 |
General and administrative | 24,866 | 25,128 | 23,558 |
Total operating expenses | 91,869 | 78,700 | 64,576 |
Income (loss) from operations | (61,869) | (76,013) | 61,586 |
Interest expense | (3,146) | (2,546) | (2,855) |
Other income, net | 1,429 | 74 | 606 |
Net income (loss) | $ (63,586) | $ (78,485) | $ 59,337 |
Net income (loss) per share - basic (in dollars per share) | $ (1.14) | $ (1.77) | $ 1.67 |
Weighted average commons shares outstanding—basic (shares) | 55,761,386 | 44,243,317 | 35,545,121 |
Net income (loss) per share - diluted (in dollars per share) | $ (1.14) | $ (1.77) | $ 1.57 |
Weighted average common shares outstanding—diluted (shares) | 55,761,386 | 44,243,317 | 38,141,793 |
Comprehensive income (loss): | |||
Net income (loss) | $ (63,586) | $ (78,485) | $ 59,337 |
Other comprehensive loss: | |||
Unrealized loss on marketable securities, net of tax | (794) | (221) | (103) |
Comprehensive income (loss) | $ (64,380) | $ (78,706) | $ 59,234 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 50,910 | $ 56,045 |
Marketable securities | 73,913 | 98,104 |
Prepaid expenses and other current assets | 4,317 | 3,197 |
Total current assets | 129,140 | 157,346 |
Property and equipment, net | 4,866 | 5,651 |
Operating lease right-of-use asset | 24,307 | 25,870 |
Restricted cash | 1,595 | 1,595 |
Other assets | 2 | 385 |
Total assets | 159,910 | 190,847 |
Current liabilities: | ||
Accounts payable | 256 | 1,550 |
Accrued expenses and other current liabilities | 10,214 | 13,089 |
Operating lease liability | 5,790 | 5,384 |
Total current liabilities | 16,260 | 20,023 |
Operating lease liability, non-current | 24,662 | 26,909 |
Convertible note payable, non-current | 25,585 | 25,015 |
Total liabilities | 66,507 | 71,947 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized at December 31, 2022 and December 31, 2021; no shares issued and outstanding at December 31, 2022 and December 31, 2021 | 0 | 0 |
Common stock, $0.0001 par value; 150,000,000 authorized at December 31, 2022 and December 31, 2021; 60,578,956 and 46,958,776 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively | 6 | 5 |
Additional paid-in capital | 298,741 | 259,859 |
Accumulated other comprehensive loss | (1,015) | (221) |
Accumulated deficit | (204,329) | (140,743) |
Total stockholders’ equity | 93,403 | 118,900 |
Total liabilities and stockholders’ equity | $ 159,910 | $ 190,847 |